A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids

STUDY QUESTION: What is the safety and efficacy profile during long-term (12–24 months) uninterrupted treatment with the selective progesterone receptor modulator asoprisnil, 10 and 25 mg in women with heavy menstrual bleeding (HMB) associated with uterine fibroids? SUMMARY ANSWER: Uninterrupted tre...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Hum Reprod Open
Hlavní autoři: Diamond, M P, Stewart, E A, Williams, A R W, Carr, B R, Myers, E R, Feldman, R A, Elger, W, Mattia-Goldberg, C, Schwefel, B M, Chwalisz, K
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6870550/
https://ncbi.nlm.nih.gov/pubmed/31777761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/hropen/hoz027
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky